Disclosure of shareholdings in accordance with Art. 20/21 SESTA
| Source: Santhera Pharmaceuticals Holding AG
Recommended Reading
-
Half Year Results for the six months ending 30 June 2026 with strong momentum and expanding global access position AGAMREE® for continued growth
Read More -
Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the...
Read More